Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/23241
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Niemiec, Emilia | - |
dc.contributor.author | Borry, Pascal | - |
dc.contributor.author | PINXTEN, Wim | - |
dc.contributor.author | Howard, Heidi Carmen | - |
dc.date.accessioned | 2017-02-28T09:01:55Z | - |
dc.date.available | 2017-02-28T09:01:55Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | HUMAN MUTATION, 37(12), p. 1248-1256 | - |
dc.identifier.issn | 1059-7794 | - |
dc.identifier.uri | http://hdl.handle.net/1942/23241 | - |
dc.description.abstract | Whole exome sequencing (WES) and whole genome sequencing (WGS) have become increasingly available in the research and clinical settings and are now also being offered by direct-to-consumer (DTC) genetic testing (GT) companies. This offer can be perceived as amplifying the already identified concerns regarding adequacy of informed consent (IC) for both WES/WGS and the DTC GT context. We performed a qualitative content analysis of Websites of four companies offering WES/WGS DTC regarding the following elements of IC: pre-test counseling, benefits and risks, and incidental findings (IFs). The analysis revealed concerns, including the potential lack of pre-test counseling in three of the companies studied, missing relevant information in the risks and benefits sections, and potentially misleading information for consumers. Regarding IFs, only one company, which provides opportunistic screening, provides basic information about their management. In conclusion, some of the information (and related practices) present on the companies' Web pages salient to the consent process are not adequate in reference to recommendations for IC for WGS or WES in the clinical context. Requisite resources should be allocated to ensure that commercial companies are offering high-throughput sequencing under responsible conditions, including an adequate consent process. (C) 2016 Wiley Periodicals, Inc. | - |
dc.description.sponsorship | Contract Grant Sponsors: Erasmus Mundus Master of Bioethics Fellowship; Erasmus Mundus Joint International Doctoral Programme in Law, Science and Technology Fellowship; Swedish Foundation for Humanities and Social Sciences (M13-0260:1); Biobanking and Molecular Resource Infrastructure of Sweden (BBMRI.se);BBMRI-ERIC; CHIP ME COST Action IS1303; FWO (Flanders-Quebec) project | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.rights | © 2016 WILEY PERIODICALS, INC. | - |
dc.subject.other | whole genome sequencing; whole exome sequencing; direct-to-consumer genetic testing; consumer genomics; informed consent | - |
dc.subject.other | whole genome sequencing; whole exome sequencing; direct-to-consumer genetic testing; consumer genomics; informed consent | - |
dc.title | Content Analysis of Informed Consent for Whole Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1256 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1248 | - |
dc.identifier.volume | 37 | - |
local.format.pages | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Niemiec, Emilia] Univ Bologna, CIRSFID, Erasmus Plus Doctoral Programme Law Sci & Technol, Via Galliera 3, I-40121 Bologna, Italy. [Niemiec, Emilia] Univ Turin, Dept Law, Turin, Italy. [Niemiec, Emilia] Leibniz Univ Hannover, Ctr Eth & Law Life Sci, Hannover, Germany. [Borry, Pascal] Katholieke Univ Leuven, Ctr Biomed Eth & Law, Dept Publ Hlth & Primary Care, Leuven, Belgium. [Pinxten, Wim] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Howard, Heidi Carmen] Uppsala Univ, Ctr Res Eth & Bioeth, Uppsala, Sweden. | - |
local.publisher.place | HOBOKEN | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1002/humu.23122 | - |
dc.identifier.isi | 000388701600002 | - |
item.contributor | Niemiec, Emilia | - |
item.contributor | Borry, Pascal | - |
item.contributor | PINXTEN, Wim | - |
item.contributor | Howard, Heidi Carmen | - |
item.validation | ecoom 2018 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Restricted Access | - |
item.fullcitation | Niemiec, Emilia; Borry, Pascal; PINXTEN, Wim & Howard, Heidi Carmen (2016) Content Analysis of Informed Consent for Whole Genome Sequencing Offered by Direct-to-Consumer Genetic Testing Companies. In: HUMAN MUTATION, 37(12), p. 1248-1256. | - |
crisitem.journal.issn | 1059-7794 | - |
crisitem.journal.eissn | 1098-1004 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
niemiec 1.pdf Restricted Access | Published version | 204.88 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
7
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
12
checked on Oct 12, 2024
Page view(s)
56
checked on Sep 6, 2022
Download(s)
48
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.